homologous recombination

Open Access
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies
IOANNIS A. VOUTSADAKIS and ATHINA STRAVODIMOU

Anticancer Research March 2023, 43 (3) 967-981; DOI: https://doi.org/10.21873/anticanres.16241
You have access
Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study
ANGIOLO GADDUCCI, STEFANIA COSIO, FABIO LANDONI, ANDREA ALBERTO LISSONI, PAOLO ZOLA, MARIA ELENA LAUDANI, ANTONIO ARDIZZOIA, ANGELA GAMBINO and ENRICO SARTORI

Anticancer Research April 2022, 42 (4) 2017-2022; DOI: https://doi.org/10.21873/anticanres.15681
You have access
Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
NAOHIRO FUJIMOTO, KENICHI HARADA, MASAKI SHIOTA, IKKO TOMISAKI, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, MIRII HARADA and MASATO FUJISAWA

Anticancer Research October 2021, 41 (10) 4687-4695; DOI: https://doi.org/10.21873/anticanres.15282
You have access
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research
ANGIOLO GADDUCCI and MARIA ELENA GUERRIERI

Anticancer Research May 2016, 36 (5) 2055-2064;
You have access
Gemcitabine Induces Radiosensitization Through Inhibition of RAD51-dependent Repair for DNA Double-strand Breaks
SHINKO KOBASHIGAWA, KEIKO MORIKAWA, HIROMU MORI and GENRO KASHINO

Anticancer Research May 2015, 35 (5) 2731-2737;
You have access
‘BRCAness’ and Its Implications for Platinum Action in Gynecologic Cancer
FRANCO MUGGIA and TAMAR SAFRA

Anticancer Research February 2014, 34 (2) 551-556;

Main menu

User menu

Search

homologous recombination